3.0
2. Feb. 2011
Aktueller Mitarbeiter
New York, NY
Empfehlen
CEO-Befürwortung
Geschäftsprognose
Pros
Good pipeline, well-known company, good "starting point" for pharma. Novartis teaches you fundamental sales skills you need to learn and sell.
Kontras
Cardiovascular portfolio puts teammates in competition with one another. Diovan going off patent in 2012- because of this there is a lull in the pipeline, it will pick up again in 2013 and beyond.